Updates are available Correction dated 2024-04-11
Click to view Correction: https://doi.org/10.1038/s43018-024-00766-5
-
Authors
Feng, Zijie https://orcid.org/0000-0002-5633-3686
He, Xin https://orcid.org/0000-0002-2131-2092
Zhang, Xuyao https://orcid.org/0000-0003-1654-5550
Wu, Yuan https://orcid.org/0000-0001-5431-0707
Xing, Bowen https://orcid.org/0000-0002-1244-8545
Knowles, Alison
Shan, Qiaonan
Miller, Samuel
Hojnacki, Taylor
Ma, Jian
Katona, Bryson W.
Gade, Terence P. F.
Siegel, Don L.
Schrader, Jörg
Metz, David C.
June, Carl H. https://orcid.org/0000-0003-0241-3557
Hua, Xianxin https://orcid.org/0000-0003-4862-4691
-
Funding
Funding for this research was provided by:
Care for Carcinoid Foundation Research Grant; Neuroendocrine Tumor Research Foundation Accelerator Grant
- License Information
-
More Information
Article History
Received: 21 May 2021
Accepted: 9 February 2022
First Online: 21 March 2022
Change Date: 11 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-024-00766-5
Competing interests
: X. Hua and Z.F. are inventors of the following patent that develops the VHH1-CAR T cells targeting CDH17: Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens, International application no. PCT/US2019/029333. Part of the patent was licensed to Chimeric Therapeutics. X. Hua is a consultant to Chimeric Therapeutics. The remaining authors declare no competing interests.
